HEK293

Increase specific influenza production with recombinant insulin

Mammalian cells are considered an alternative to eggs for the production of influenza vaccines. HEK293SF-3F6 is a suspension GMP cell line that grows in serum-free media, and influenza production has been achieved in flasks and large bioreactors.

National Research Council Canada (NRC)  in collaboration with Novo Nordisk Pharmatech (world’s largest supplier of recombinant insulin) has shown that addition of animal origin free insulin to commercial available media and in-house proprietary media in HEK 293SF-3F6 batch-mode culture, resulted in significant increases in cell growth, leading up to 4-fold increase compared to insulin free media formulations.

In addition to cell growth, the study aimed to address the effect of Insulin on HEK-based Influenza Production, since the effect on Influenza virus productivity was not known.

Insulin has been proved already to positively affect cell survival, by promoting anti-apoptotic and mitogenic pathways, to interact on cellular signalling pathways that are exploited by the influenza virus and it has the benefit of being already approved by regulatory agencies.

This study has shown that addition of animal origin free insulin to commercial available media and in-house proprietary media in HEK 293SF-3F6 micro-bioreactor culture, resulted in significant increase in H1N1 and H3N2 Influenza subtypes , leading to up to 1,9-fold increase compared to insulin free media formulations.

You can read the full whitepaper or read the poster behind the study

Contact

Sara Gualdoni

Product Manager

Email

Direct phone: +45 3199 5935